Kepler Capital Markets Analysts Give Bayer (BAYN) a €84.00 Price Target

Bayer (FRA:BAYN) has been assigned a €84.00 ($97.67) price objective by equities researchers at Kepler Capital Markets in a report issued on Thursday. The firm presently has a “buy” rating on the healthcare company’s stock. Kepler Capital Markets’ price objective indicates a potential upside of 31.64% from the company’s previous close.

Several other analysts have also recently commented on the company. JPMorgan Chase & Co. reissued a “buy” rating on shares of Bayer in a report on Monday, October 22nd. Credit Suisse Group set a €95.00 ($110.47) price target on Bayer and gave the company a “buy” rating in a report on Friday, October 26th. Berenberg Bank set a €113.00 ($131.40) price target on Bayer and gave the company a “buy” rating in a report on Monday, August 27th. Jefferies Financial Group set a €77.00 ($89.53) price target on Bayer and gave the company a “neutral” rating in a report on Tuesday, October 23rd. Finally, Goldman Sachs Group set a €78.00 ($90.70) price target on Bayer and gave the company a “buy” rating in a report on Tuesday, November 20th. Six analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of €91.80 ($106.74).

BAYN opened at €63.81 ($74.20) on Thursday. Bayer has a 12 month low of €91.58 ($106.49) and a 12 month high of €123.82 ($143.98).

About Bayer

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

Recommended Story: How to Calculate Compound Annual Growth Rate (CAGR)

Analyst Recommendations for Bayer (FRA:BAYN)

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply